Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (621-630 of 993) with videos related to

Pageof 100
Sort By:
Frontiers in Oncology|December 23, 2022
Predicting the probability of pT3 or higher pathological stage at radical prostatectomy: COVID19-specific considerationsLuigi Nocera, Lara F Stolzenbach, Claudia Collà Ruvolo, et al.
International Journal of Radiation Oncology, Biology, Physics|May 7, 2023
Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT TrialPeter Meidahl Petersen, Adrian D Cook, Matthew R Sydes, et al.
European Urology|April 11, 2020
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 TrialDavid P Dearnaley, Daniel R Saltzstein, John E Sylvester, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 18, 2015
Prevalence and risk factors of contralateral extraprostatic extension in men undergoing radical prostatectomy for unilateral disease at biopsy: A global multi-institutional experienceMarc Bienz, Pierre-Alain Hueber, Vincent Trudeau, et al.
European Urology Focus|March 3, 2021
Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific ValidationLuigi Nocera, Claudia Collà Ruvolo, Lara F Stolzenbach, et al.
World Journal of Urology|April 28, 2024
Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancerLukas Scheipner, Andrea Baudo, Letizia Maria Ippolita Jannello, et al.
Urologic Oncology|April 18, 2022
Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicityGabriele Sorce, Francesco Chierigo, Rocco Simone Flammia, et al.
European Urology|March 9, 2023
Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 TrialSoumyajit Roy, Yilun Sun, Scott C Morgan, et al.
Radiation Oncology (London, England)|April 26, 2019
Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostateVincent Q Trinh, Nazim Benzerdjeb, Ségolène Chagnon-Monarque, et al.
Urologic Oncology|May 27, 2014
Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract CollaborationVincent Fradet, Julian Mauermann, Wassim Kassouf, et al.
Pageof 100

Showing results (621-630 of 993) with videos related to

Sort By:
Pageof 100
Frontiers in Oncology|December 23, 2022
Predicting the probability of pT3 or higher pathological stage at radical prostatectomy: COVID19-specific considerationsLuigi Nocera, Lara F Stolzenbach, Claudia Collà Ruvolo, et al.
International Journal of Radiation Oncology, Biology, Physics|May 7, 2023
Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT TrialPeter Meidahl Petersen, Adrian D Cook, Matthew R Sydes, et al.
European Urology|April 11, 2020
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 TrialDavid P Dearnaley, Daniel R Saltzstein, John E Sylvester, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 18, 2015
Prevalence and risk factors of contralateral extraprostatic extension in men undergoing radical prostatectomy for unilateral disease at biopsy: A global multi-institutional experienceMarc Bienz, Pierre-Alain Hueber, Vincent Trudeau, et al.
European Urology Focus|March 3, 2021
Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific ValidationLuigi Nocera, Claudia Collà Ruvolo, Lara F Stolzenbach, et al.
World Journal of Urology|April 28, 2024
Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancerLukas Scheipner, Andrea Baudo, Letizia Maria Ippolita Jannello, et al.
Urologic Oncology|April 18, 2022
Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicityGabriele Sorce, Francesco Chierigo, Rocco Simone Flammia, et al.
European Urology|March 9, 2023
Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 TrialSoumyajit Roy, Yilun Sun, Scott C Morgan, et al.
Radiation Oncology (London, England)|April 26, 2019
Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostateVincent Q Trinh, Nazim Benzerdjeb, Ségolène Chagnon-Monarque, et al.
Urologic Oncology|May 27, 2014
Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract CollaborationVincent Fradet, Julian Mauermann, Wassim Kassouf, et al.
Pageof 100